These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
8. Long-term hearing outcome in patients receiving intratympanic gentamicin for Ménière's disease. Wu IC; Minor LB Laryngoscope; 2003 May; 113(5):815-20. PubMed ID: 12792316 [TBL] [Abstract][Full Text] [Related]
9. Different medications for the treatment of Ménière's disease by intratympanic injection: A systematic review and network meta-analysis. Cao Z; Yue F; Huang W; Rajenderkumar D; Zhao F Clin Otolaryngol; 2019 Jul; 44(4):619-627. PubMed ID: 31025490 [TBL] [Abstract][Full Text] [Related]
10. Intratympanic mixture gentamicin and dexamethasone versus dexamethasone for unilateral Meniere's disease. Öztürk K; Ata N Am J Otolaryngol; 2019; 40(5):711-714. PubMed ID: 31262549 [TBL] [Abstract][Full Text] [Related]
11. Modified titration intratympanic gentamicin injection for unilateral intractable Ménière's disease. Liu B; Leng YM; Shi H; Zhou RH; Liu JJ; Zhang WJ; Zhang SL; Kong WJ J Huazhong Univ Sci Technolog Med Sci; 2015 Oct; 35(5):747-751. PubMed ID: 26489633 [TBL] [Abstract][Full Text] [Related]
12. Intratympanic gentamicin for control of vertigo in Meniere's disease: vestibular signs that specify completion of therapy. Minor LB Am J Otol; 1999 Mar; 20(2):209-19. PubMed ID: 10100525 [TBL] [Abstract][Full Text] [Related]
14. Endolymphatic sac surgery versus intratympanic gentamicin for the treatment of intractable Ménière's disease: a retrospective review with survey. Paradis J; Hu A; Parnes LS Otol Neurotol; 2013 Oct; 34(8):1434-7. PubMed ID: 23846192 [TBL] [Abstract][Full Text] [Related]
15. Role of prior intratympanic gentamicin and corticosteroids therapy on speech understanding in patients with Menière's disease after cochlear implantation. Thangavelu K; Gillhausen F; Weiß RM; Mueller-Mazzotta J; Stuck BA; Reimann K Eur Arch Otorhinolaryngol; 2024 Jul; 281(7):3483-3490. PubMed ID: 38302621 [TBL] [Abstract][Full Text] [Related]
16. End-point indicators of low-dose intra-tympanic gentamicin in management of Ménière's disease. Liu H; Zhang T; Wu Q; Zhang Y; Dai C Acta Otolaryngol; 2017 Feb; 137(2):136-143. PubMed ID: 27608722 [TBL] [Abstract][Full Text] [Related]
18. Intratympanic gentamicin for Ménière's disease: effect on quality of life as assessed by Glasgow benefit inventory. Banerjee AS; Johnson IJ J Laryngol Otol; 2006 Oct; 120(10):827-31. PubMed ID: 16707038 [TBL] [Abstract][Full Text] [Related]
19. A comparison of endolymphatic shunt surgery and intratympanic gentamicin for meniere's disease. Gibson AW; Moon IJ; Golub JS; Rubinstein JT Laryngoscope; 2020 Oct; 130(10):2455-2460. PubMed ID: 31808957 [TBL] [Abstract][Full Text] [Related]
20. CASP9 genotype confers gentamicin susceptibility in intratympanic treatment of intractable vertigo caused by Ménière's disease. Huang CJ; Wan TK; Fang TY; Wang PC Acta Otolaryngol; 2019 Apr; 139(4):336-339. PubMed ID: 30907242 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]